On September 23, 2026, Jaguar Health, Inc. entered into privately negotiated exchange agreements with Streeterville Capital, LLC to reduce outstanding debt obligations. The transactions, filed as part of a Current Report on Form 8-K, involve the issuance of common stock in exchange for a reduction of the principal balance on two promissory notes issued to Streeterville.
Under the terms of the first agreement, the Company issued an aggregate of 182,091 shares of common stock to Streeterville. This exchange resulted in a reduction of the outstanding balance on the 2021 Note by $1,678,320. The 2021 Note was originally issued on January 19, 2021, with an original principal amount of $6,220,812.50.
The second agreement involved the issuance of 547,898 shares of common stock to Streeterville. This exchange reduced the outstanding balance of the 2025 Note by $5,049,909.26. The 2025 Note was originally issued on November 12, 2025, with an original principal amount of $10,810,000. Upon completion of this transaction, the 2025 Note was fully paid and cancelled.
The shares issued in these transactions were registered under an exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933. As of September 24, 2026, the Company reported having approximately 1,463,958 shares of Common Stock issued and outstanding.
